Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coegin PharmaNGM:COEGIN -2.00%27 EV-to-EBITDA is -4.72 as of Aug. 24, 2026. GuruFocus rates NGM:COEGIN with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 408 Biotechnology companies, Coegin Pharma ranks worse than 245097.79% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Coegin Pharma's enterprise value is kr78.15 Mil.
Coegin Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr-16.57 Mil. Therefore, Coegin Pharma's EV-to-EBITDA for today is -4.72.
The historical rank and industry rank for Coegin Pharma's EV-to-EBITDA or its related term are showing as below:
NGM:COEGIN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.8 Med: -0.07 Max: -0.05
Current: -4.64
During the past 9 years, the highest EV-to-EBITDA of Coegin Pharma was -0.05. The lowest was -5.80. And the median was -0.07.
NGM:COEGIN's EV-to-EBITDA is ranked worse than 100% of 408
companies
in the Biotechnology industry
Industry Median: 14.13
vs NGM:COEGIN: -4.64
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Coegin Pharma's PE Ratio (TTM) for today is calculated as:
Coegin Pharma's share price for today is kr2.94.
Coegin Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.790.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Coegin Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:COEGIN vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Coegin Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coegin Pharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coegin Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Coegin Pharma's EV-to-EBITDA falls into.
Coegin Pharma's current Enterprise Value is kr78.15 Mil.
Coegin Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-16.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coegin Pharma (NGM:COEGIN) has a EV-to-EBITDA of -4.72 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Coegin Pharma. According to the industry distribution chart, Coegin Pharma ranks #999999 out of 408 companies in the Biotechnology industry.
Is Coegin Pharma's EV-to-EBITDA too high?
Coegin Pharma's current EV-to-EBITDA is -4.72. Based on the distribution chart, Coegin Pharma ranks #999999 out of 408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coegin Pharma has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Coegin Pharma ranks #999999 out of 408 companies for EV-to-EBITDA. This places Coegin Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 14.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.13, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Coegin Pharma. For the Biotechnology industry, the median EV-to-EBITDA is 14.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coegin Pharma's current EV-to-EBITDA is -4.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current EV-to-EBITDA of -4.72. The current EV-to-EBITDA is -4.72. Coegin Pharma's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current EV-to-EBITDA is -4.72 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
27GF Score
Get the complete analysis for NGM:COEGIN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:COEGIN has been successfully added to your 
